The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

VIP Salvage Chemotherapy for Poor-Prognosis Germ Cell Tumors

Etoposide, ifosfamide and cisplatin salvage regimen for refractory or relapsed germ cell tumors after BEP failure

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is VIP Salvage Chemotherapy for Poor-Prognosis Germ Cell Tumors?

VIP combines etoposide, ifosfamide and cisplatin as salvage chemotherapy for germ cell tumors.

International Germ Cell Consensus Classification stratifies prognosis based on primary site, metastasis pattern and tumor markers.

Salvage indications include relapsed disease after BEP, refractory disease, or initial poor-prognosis features.

Cure rates with VIP salvage range from 25-50% depending on prognostic factors and prior treatment.

High-dose chemotherapy with autologous stem cell transplant offers further salvage option for select patients.

Symptoms

Severe myelosuppression including febrile neutropenia requires aggressive supportive care.
Hemorrhagic cystitis from ifosfamide requires mesna prophylaxis and aggressive hydration.
Ifosfamide encephalopathy with confusion, seizures, coma requires methylene blue and supportive care.
Nephrotoxicity from cisplatin requires aggressive hydration and electrolyte monitoring.
Ototoxicity, peripheral neuropathy, secondary malignancies represent long-term cisplatin and etoposide toxicities.

Risk Factors

Mediastinal non-seminomatous germ cell tumors carry poor prognosis with cure rates approximately 50%.
Non-pulmonary visceral metastases including liver, brain, bone indicate poor prognosis disease.
Markedly elevated alpha-fetoprotein, beta-hCG or lactate dehydrogenase indicates higher risk disease.
Late relapse occurring more than 2 years after primary therapy carries worse prognosis.
Cisplatin-refractory disease defined as progression during or within 4 weeks of cisplatin-based therapy has limited salvage potential.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Germ cell tumor relapse after BEP or refractory disease warrants salvage chemotherapy consideration.
  • Specialized testicular cancer center referral with experienced multidisciplinary teams optimizes outcomes.
  • Severe febrile neutropenia, hemorrhagic cystitis, ifosfamide encephalopathy, nephrotoxicity require urgent management.
  • Tumor marker re-elevation during surveillance warrants restaging and salvage therapy consideration.
  • Comprehensive surveillance including tumor markers, imaging, organ function monitoring during treatment essential.

Treatment Methods

01
VIP regimen: etoposide 75 mg/m² days 1-5, ifosfamide 1.2 g/m² days 1-5 with mesna, cisplatin 20 mg/m² days 1-5 every 21 days.
02
Mesna prophylaxis with hydration for hemorrhagic cystitis prevention essential during ifosfamide.
03
Aggressive hydration, electrolyte management, growth factor support reduce treatment-related morbidity.
04
Surgical resection of residual masses after chemotherapy essential for non-seminoma management.
05
Comprehensive multidisciplinary care with medical oncology, urologic oncology, surgery, supportive care, antiemetic prophylaxis, infection prophylaxis, fertility preservation, high-dose chemotherapy with autologous stem cell transplant for selected patients with cisplatin-sensitive relapse, post-treatment surveillance with tumor markers and imaging, second-line salvage with TIP (paclitaxel, ifosfamide, cisplatin) for further relapse, and survivorship care addressing long-term cisplatin and etoposide toxicities optimizes outcomes for patients with poor-prognosis or relapsed germ cell tumors.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.